The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1529
Deflazacort (Emflaza) for Duchenne Muscular Dystrophy
The full article is available to subscribers Subscriber Login   

Deflazacort (Emflaza – PTC Therapeutics), an oral corticosteroid, has been approved by the FDA for treatment of Duchenne muscular dystrophy (DMD) in patients ≥5 years old. It has been available outside the US for many years. Deflazacort is the second drug to be approved for treatment of DMD; eteplirsen (Exondys 51), an antisense oligonucleotide approved for IV administration in patients with mutations of the dystrophin gene amenable to exon 51 skipping (about 13% of DMD cases), was the first.1

THE DISORDER — DMD is a progressive, X-linked, recessive, neuromuscular disorder characterized by decreased levels or complete absence of the protein dystrophin in muscle cells. Dystrophin is essential for maintenance of myocyte integrity. About 1 in 5000 infant males has DMD. Patients with DMD begin experiencing progressive muscle weakness and deterioration when they ... more       Show References Hide References

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Deflazacort (Emflaza) for Duchenne Muscular Dystrophy
Article code: 1529d
 Electronic, downloadable article - $25